PVP Biologics Gets $35M From Takeda

San Diego-based biopharmaceuticals firm PVP Biologics, which is developing treatments for celiac disease, has received $35M from Takeda Pharmaceutical Company Limited, the companies announced on Thursday. The two said that Takeda will fund $35M in expenses for PVP Biologics, in exchange for an exclusive option to acquire PvP. PVP said it is developing an enzyme therapy, which breaks down the immune-reactive parts of gluten in the stomach, which cause the painful symptoms and damage due to gluten ingestion in patients.